Health
LegoChem Biosciences and Iksuda Therapeutics expand License Agreement for development of antibody-drug conjugates – News-Medical.net
Iksuda Therapeutics today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences,…
Iksuda Therapeutics, the developer of a new generation of antibody drug conjugates (ADCs) with raised therapeutic index, today announced that it has expanded its research collaboration and License Agreement with LegoChem Biosciences, Inc. (“LCB”) to explore…
Continue Reading
-
General21 hours agoAbattoir worker in serious condition after workplace accident in Echuca
-
General21 hours agoWoman who reported NSW MP Gareth Ward’s alleged sex crimes cross-examined
-
Noosa News12 hours agoFull house as Minister shares vision for Sunshine Coast transport
-
General13 hours agoIran-Israel war live updates: Missiles fired at US bases in Qatar as war expands